Abstract. Genetic mutation of breast cancer 1 (BRCA1) is one of the most notable factors responsible for a proportion of breast cancer cases. BRCA1 encodes a 1,863-amino acid protein and functions as a negative regulator of tumor growth. Thus, investigation of the underlying mechanisms that regulate BRCA1 gene expression provide further insight into possible targets for breast cancer therapy. Previous studies have demonstrated that the genetic variants in the BRCA1 3' untranslated region (3'UTR), in addition to the cytosine-phosphate-guanine (CpG) islands in the promoter region, are significantly associated with breast cancer risk; however, the role of single nucleotide polymorphisms (SNPs) in the BRCA1 3'UTR remains unclear. The present study aimed to investigate the association between SNPs and BRCA1 mRNA expression levels. Bioinformatics analysis demonstrated that 2 SNPs in the BRCA1 3'UTR (rs12516 and rs8176318 with putative microRNA binding sites) were significantly correlated with mRNA expression in lymphoblastoid cell lines (P=2.55x10 , respectively). Furthermore, the genotype frequency distribution varied between populations worldwide. In addition, 3 CpG islands and several transcription factor binding sites in the BRCA1 promoter region were established. The identification of such polymorphisms and CpG islands may aid in designing improved therapeutic strategies to treat patients with BRCA1-associated breast cancer.
Introduction
According to the current literature, breast cancer is the most commonly diagnosed form of cancer and is the principal cause of cancer-associated fatality among females. The disease accounts for 14% of all cancer mortalities, particularly in economically-developing countries, and 23% of all cancer cases (1) . The breast cancer 1 (BRCA1) gene is ~100 kb in length and is localized to chromosome 17q21; it is composed of 24 exons, with 22 of these translating into a 1,863 amino acid protein. It is currently well-established that mutations in the BRCA1 gene result in a significantly increased lifetime risk for the development of breast cancer (2) . Thus, BRCA1, functioning as a tumor suppressor, may be regarded as a strong candidate gene for breast cancer susceptibility.
The abnormal methylation of cytosine-phosphate-guanine (CpG) islands in gene promoter regions is the predominant epigenetic mechanism by which gene transcription is effectively silenced; therefore, the transcriptional activity of genes with CpG island promoters is suppressed upon methylation (3) . Notably, a previous study concluded that microRNAs (miRNAs/miRs) may function as oncogenes and tumor suppressors depending on the genetic variants in the 3'UTR binding sites, regulating gene expression post-transcriptionally (4) . For example, miR-146a was observed to bind to the 3'UTR of BRCA1 and BRCA2 mRNA, potentially modulating their mRNA expression, and a genetic polymorphism in the miR-146a gene (rs2910164) was associated with a young diagnostic age of familial ovarian and breast cancer (5) . However, the function of genetic variants in miRNA binding sites of BRCA1 remains unclear. In the current study, the hypothesis that the BRCA1 3'UTR variants are associated with its mRNA expression was tested by performing bioinformatics analysis. In addition, the CpG islands and transcription factor binding sites (TFBSs) were predicted.
Materials and methods

Prediction of the CpG islands and TFBSs in the promoter
region. The human BRCA1 promoter region was obtained by searching the UCSC Genome Bioinformatics online database (www.genome.ucsc.edu/). The core promoters were identified by Neural Network Promoter Prediction (NNPP; www.fruitfly.org/seq_tools/promoter.html) and Promoter2.0 (www.cbs.dtu.dk/services/promoter/), and the CpG islands were predicted using the bioinformatics tool MethPrimer (www.urogene.org/methprimer/). The criteria used to define a CpG island was as follows: Island size, >100 bp; GC percentage, >50.0; and observed/expected ratio, >0.6. In addition, the TFBSs were predicted by JASPAR (jaspar.genereg.net/). 
Results
CpG islands and TFBSs in the BRCA1 promoter region. The online tools NNPP and Promoter2.0 indicated that there were several core promoter regions located in the target sequence. A total of 3 core promoter regions were determined by NNPP, whilst Promoter2.0 identified 2 core promoter regions. The bioinformatics software MethPrimer was used to predict the range of the CpG islands in the BRCA1 gene. The results determined that there were 3 CpG islands in the BRCA1 promoter region ( Fig. 1 ; Table I ), which may serve a crucial role in the expression of the BRCA1 gene. In total, 31 transcription factors and 45 binding sites were predicted in the target sequence regions when limiting the relative profile score threshold to >95%.
BRCA1 3'UTR selected variants and their putative miRNA binding sites.
A total of 28 SNPs were identified in the human BRCA1 3'UTR; 13 of these SNPs had available minor allele frequency (MAF) values, 2 of which (rs12516 and rs8176318) had MAF values >0.05. SNP Function Prediction demonstrated that these 2 SNPs exhibited putative miRNA binding sites (Table II) . As presented in Table II , the C-to-thymine (T) transition mutation, rs12516, had 6 potential miRNA binding sites, namely, hsa-miR-188-5p, hsa-miR-502-5p, hsa-miR-557, hsa-miR-623, hsa-miR-637 and hsa-miR-639. The G-to-T transition mutation, rs8176318, was observed to share hsa-miR-639 with rs12516, and contain 4 other miRNA binding sites, namely, hsa-miR-1182, hsa-miR-149, hsa-miR-345 and hsa-miR-544.
Frequency distribution of selected variants among distinct populations. As previously reported, the derived alleles at rs12516 and rs8176318 in the BRCA1 3'UTR demonstrated a positive association with familial ovarian and breast cancer in Thai women, and the 2 SNPs were in strong linkage disequilibrium in populations and varied by ethnicity (8) . In the present study, in order to better evaluate the global genotypes of rs12516 and rs8176318 in BRCA1, the frequency distribution data of these variants across 11 worldwide populations were summarized (Tables III and IV) . The 2 SNPs presented differences in genotype frequency distribution among the worldwide populations. For rs12516, the genotype frequencies of CC, CT and TT were highest in YRI (69.0%), CHD (57.6%) and GIH (18.2%). The frequency distributions of the GG, GT and TT genotypes of rs8176318 ranked first among LWK (84.4%), CHD (56.6%) and GIH (18.2%). The T allele frequencies of rs12516 in the various populations ranged between 44.9% in GIH and 17.3% in YRI. Notably, the frequency distributions of the GG, GT and TT genotypes of rs8176318 were the same as the data for CC, CT and TT genotypes of rs12516 among the CEU and CHB populations.
LD of all SNPs in the BRCA1 gene calculation.
SNPs not in LD (r 2 <0.8) were selected and LD maps of those SNPs in the BRCA1 gene were plotted using the SNP Function Prediction program to identify the potential functional relevance of all selected SNPs (Fig. 2) . The degree of pairwise LD between all SNPs was estimated as quantified by the disequilibrium coefficient (D') and r 2 , which represented the proportion of disequilibrium and the maximum possible disequilibrium given for observed allele frequencies, respectively. The higher the D' value, the greater the association between the two loci being studied. The color of each SNP spot reflects its D' value, which changes from red to white as it decreases. The MAF of each aforementioned allele was >0.05. As for the SNPs in the BRCA1 3'UTR, only rs12516 and rs8176318 were included in the LD plot, but neither were the predicted tag SNP. ; Fig. 3A) . Similarly, the rs8176318 GG genotype had a significantly lower expression level than the GT and TT genotypes (P=8.78x10 -5 ; Fig. 3B ).
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Discussion
Since the identification of the BRCA1 gene 20 years ago (9), the biological basis underlying the high breast cancer risk in women with BRCA1 mutations has gained increasing attention. BRCA1 operates in a series of cellular processes, including DNA repair, chromatin remodeling, protein ubiquitination, regulation of transcription, apoptosis and cell cycle checkpoint control. As observed in carriers of germline BRCA1 mutations, the disruption of any of the aforementioned processes may result Table IV . Genotype frequency of the breast cancer 1 gene rs8176318 polymorphism in different populations. in an increased risk for carcinogenesis (10) . Dacheux et al (11) demonstrated that BRCA1 modified the translational regulation of ~7% of genes expressed in MCF7 cells, including structural maintenance of chromosomes 6, thyroid hormone receptor α and topoisomerase I. It was proposed that BRCA1 may serve a direct transcriptional role in the regulation of p27 Kip1 resulting in S-phase arrest; this suggested that the BRCA1-mediated transcriptional regulation of p27
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Kip1 may function as a mechanism for BRCA1-induced growth inhibition (12) .
BRCA1 promoter methylation is considered to serve a key role in the etiology of human breast cancer. Iwamoto et al (13) reported that BRCA1 promoter methylation in peripheral blood cells may establish a novel risk factor for the development of breast cancer. Xu et al (14) demonstrated that methylation of the BRCA1 promoter was associated with increased mortality rates among women with breast cancer. The promoter region of the BRCA1 gene was methylated in a large proportion of Taiwanese patients with early-stage breast cancer, and patients with BRCA1-methylated tumors exhibited poorer survival outcomes (15) . A meta-analysis provided evidence that methylation of the BRCA1 promoter was associated with the poor survival of patients with breast cancer (16) . To directly investigate 
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BRCA1 gene regulation on a transcriptional level, the present study predicted 3 CpG islands and several putative TFBSs in the BRCA1 promoter region using bioinformatics analysis. Previous studies have demonstrated that BRCA1 3'UTR miRNA binding site variants are associated with breast cancer risk post-translationally. For example, miR-24 was observed to directly target the 3'UTR of BRCA1 and resulted in significant repression of the BRCA1 gene (17) . In addition, it was demonstrated that the BRCA1 polymorphism, rs799917, was associated with breast cancer risk (18) . By contrast, Hasan et al (19) reported that rs799917 demonstrated no significant association with breast cancer in 100 patients with breast cancer in Saudi Arabia (19) . Therefore, the role of genetic variants in the BRCA1 3'UTR and its post-transcriptional regulation remains unclear. Such differences may be due to reproductive patterns, in addition to exposure to particular environmental carcinogens, different lifestyles and different genetic backgrounds (19) . The present study focused on the polymorphisms in the BRCA1 3'UTR, and identified that rs12516 and rs8176318 had potential miRNA binding sites. Furthermore, rs12516 and rs8176318 exhibited differences in genotype frequency distribution among populations worldwide. Each SNP had a significant association with BRCA1 mRNA expression, therefore implying that these SNPs may partially contribute to BRCA1 post-transcriptional regulation.
In conclusion, the current study predicted 3 GpG islands, 45 TFBSs located in the promoter region and 13 SNPs located in the 3'UTR of the BRCA1 gene. A total of 4 SNPs (rs8176320, rs12516, rs8176318 and rs56108540) were confirmed to have putative miRNA binding sites, among which only 2 (rs12516 and rs8176318) had MAF values >0.05. These 2 SNPs, rs12516 and rs8176318, each demonstrated a significant association with BRCA1 mRNA expression. The results from the present study have raised the possibility that rs12516 and rs8176318 may be associated with an increased risk of breast cancer by altering the BRCA1 mRNA level. However, such results require substantiation by experimental data, therefore further investigations are warranted to confirm the function of these polymorphisms. In addition, further functional analysis is necessary to validate the promoter CpG islands and SNPs in the 3'UTR to allow for investigation of BRCA1 gene regulation as a potential therapy for breast cancer.
